Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers

Basit Öğe Kaydı
dc.contributor.authorErdogan, M.
dc.contributor.authorSolmaz, S.
dc.contributor.authorCanataroglu, A.
dc.contributor.authorKulaksizoglu, M.
dc.contributor.authorCetinkalp, S.
dc.contributor.authorOzgen, A. G.
dc.contributor.authorSaygili, F.
dc.contributor.authorYilmaz, C.
dc.date.accessioned2019-10-27T21:17:05Z
dc.date.available2019-10-27T21:17:05Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractPlasma TAFI may participate in arterial thrombosis in cardiovascular diseases (CVD) and may be involved in the mechanism of vascular endothelial damage in diabetic patients. The aim of this study was to investigate the association of plasma TAFI antigen level in the development of diabetic foot ulcer in Type 2 diabetes. The TAFI antigen levels were determined in 50 patients with diabetic foot ulcers and 34 patients without diabetic foot ulcers and 25 healthy individuals. We measured TAFIa/ai antigen in plasma samples with a commercially available ELISA Kit. Diabetic foot ulcer group and diabetic group were similar in terms of mean age and sex distribution. Diabetes duration, retinopathy, neuropathy, macrovascular disease and infection were related to diabetic foot ulcers. HbA1c, HDL-cholesterol and Folic Acid levels were decreased in the diabetic foot ulcer group. TAFI levels were 99.44 +/- A 55.94% in control group, 135.21 +/- A 61.05% in diabetic foot ulcer group, 136.75 +/- A 59.38% in diabetic group and was statistically different (P < 0.05). But no difference was seen in TAFI levels between the diabetic foot ulcer group and diabetic group (P > 0.05). No significant difference in plasma TAFI levels were seen between diabetic foot ulcer stages. TAFI antigen levels are increased in Type 2 diabetic patients, but are not related to diabetic foot ulcer development.en_US
dc.identifier.doi10.1007/s12020-010-9329-1en_US
dc.identifier.endpage454en_US
dc.identifier.issn1355-008X
dc.identifier.issue3en_US
dc.identifier.pmid20960167en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.1007/s12020-010-9329-1
dc.identifier.urihttps://hdl.handle.net/11454/43770
dc.identifier.volume37en_US
dc.identifier.wosWOS:000277199600012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofEndocrineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTAFI antigenen_US
dc.subjectDiabetic foot ulcersen_US
dc.subjectType 2 diabetesen_US
dc.titlePlasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu